Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Preferred Stock Liabilities (2019 - 2020)

Biodesix filings provide 2 years of Preferred Stock Liabilities readings, the most recent being $194.0 million for Q3 2020.

  • On a quarterly basis, Preferred Stock Liabilities changed 0.0% to $194.0 million in Q3 2020 year-over-year; TTM through Sep 2020 was $194.0 million, a 0.0% change, with the full-year FY2019 number at $194.0 million, changed N/A from a year prior.
  • Preferred Stock Liabilities hit $194.0 million in Q3 2020 for Biodesix, roughly flat from $194.0 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $194.0 million in Q3 2019 to a low of $194.0 million in Q3 2019.